MedTrace Logo

Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections

NCT01037192 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2015-08-27

Study results available
· View outcomes & findings →

Summary

Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for skin and soft tissue infections in an outpatient setting.

Conditions

  • Skin and Soft Tissue Infections

Interventions

DRUG

vancomycin

vancomycin 30 mg/kg intravenous administered once daily

DRUG

vancomycin

vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)

Sponsors & Collaborators

  • Fraser Health

    lead OTHER

Principal Investigators

  • Anna Yuen, BSc. Pharm · Fraser Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01037192 on ClinicalTrials.gov